EAST WINDSOR, N.J. – Aurobindo Pharma Limited has acquired clorazepate dipotassium tablets 3.75mg, 7.5mg and 15mg from Mylan Pharmaceuticals, a Viatris Co.. Mylan has agreed to transfer the FDA-approved ANDA for each of these products to Aurobindo Pharma USA, Inc. and Aurobindo will begin to market, distribute, and sell these products as of January 1, 2021.

Clorazepate dipotassium tablets are indicated for the management of anxiety disorders, for short-term relief of the symptoms of anxiety, and as an adjunctive therapy in the management of partial seizures.

Paul McMahon, senior vice president of Commercial Operations for Aurobindo, commenting on the news said that “We are very pleased to add yet another important product to our expansive portfolio of generics, and specifically to our broad line of mental health and anti-depressive treatment options.”